The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•21 April 2026•

1 min read

Charles River Validates Virtual Control Groups in Toxicology to Reduce Animal Testing

Key Facts

1A retrospective analysis demonstrated 100% concordance in No Observed Adverse Effect Levels (NOAEL) using Virtual Control Groups (VCGs).

Charles River Laboratories has published peer-reviewed evidence confirming that Virtual Control Groups (VCGs) can successfully replace live animal control groups in toxicology studies. A retrospective analysis demonstrated 100% concordance in No Observed Adverse Effect Levels (NOAEL), validating the scientific integrity of this digital approach. This initiative is a core component of the Alternative Methods Advancement Project (AMAP), which seeks to reduce the industry's reliance on animal models. By leveraging advanced analytics, the company aims to enhance ethical standards and increase efficiency in drug safety assessments. This breakthrough is expected to improve operational efficiency and strengthen Charles River's ESG positioning by potentially lowering costs and accelerating study timelines. The validation of VCGs marks a significant milestone in the digital transformation of pharmaceutical R&D.